An analysis of the safety of Sevoflurane drugs: A disproportionality analysis based on Food and Drug Administration Adverse Event Reporting System

Xinxia Yang,Yiming Shen,Hang Chen,Dongdong Chen
DOI: https://doi.org/10.1097/md.0000000000038873
IF: 1.6
2024-09-02
Medicine
Abstract:Sevoflurane was first discovered by Pos Terell and successfully synthesized by Regan in 1968. [ 1 ] However, it was not put into clinical use until phase III clinical trial from Japan in 1986, which was related to the potential AEs it may have. [ 2 ] Sevoflurane is a colorless, transparent, aromatic, and nonvolatile liquid with stable chemical properties. At commonly used clinical concentrations, it will not burn or explode when in contact with oxygen. [ 3 ] Due to its pleasant odor and nonirritating effect on trachea, Sevoflurane is permitted for inhalation induction in children and adults. [ 4 ] In inhalation anesthesia, 95% to 98% of Sevoflurane is excreted through the lungs, while the rest is excreted through the liver and kidney pathways. [ 5 ] Since its launch, there have been many reports of adverse events related to Sevoflurane, including neurological, respiratory, and circulatory systems. However, overall, Sevoflurane is considered a relatively safe and reliable drug. [ 6 ] This study aims to explore the unreported adverse reactions of Sevoflurane through the FDA adverse event reporting system (FAERS) database.
medicine, general & internal
What problem does this paper attempt to address?